Inflammation Research

Papers
(The H4-Index of Inflammation Research is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
News335
Unveiling the role of ABI3 and hub senescence-related genes in macrophage senescence for atherosclerotic plaque progression221
Inhibition of glycolytic reprogramming suppresses innate immune-mediated inflammation in experimental amyotrophic lateral sclerosis171
Paradoxical expression of NRP1 in decidual stromal and immune cells reveals a novel inflammation balancing mechanism during early pregnancy114
Kinin B1 receptor and TLR4 interaction in inflammatory response96
Loss of TRIM24 promotes IL-10 expression via CBP/p300-dependent IFNβ1 transcription during macrophage activation92
Immunity-related GTPase IRGM at the intersection of autophagy, inflammation, and tumorigenesis89
Beyond CYP2C19: inflammation and angiogenesis gene variants drive clopidogrel resistance in CAD patients76
Long-chain acyl-CoA synthetase 4-mediated mitochondrial fatty acid metabolism and dendritic cell antigen presentation68
Serum from COVID-19 patients promotes endothelial cell dysfunction through protease-activated receptor 268
Viperin inhibits interferon-γ production to promote Mycobacterium tuberculosis survival by disrupting TBK1-IKKε-IRF3-axis and JAK-STAT signaling60
Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis59
Immune-related genetic single-nucleotide polymorphisms contribute to prognosis and response to chemotherapy in patients with acute lymphoblastic leukemia59
CD20+ T cells: an emerging T cell subset in human pathology57
Tissue-resident immune cells in the pathogenesis of multiple sclerosis56
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target50
Single-cell hdWGCNA reveals a novel diagnostic model and signature genes of macrophages associated with chronic obstructive pulmonary disease50
From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases47
IL10/AMPK pathway was associated with the hippocampal anti-inflammatory response to high-sugar and high-fat diet withdrawal46
The role of fatty acid metabolism on B cells and B cell-related autoimmune diseases46
Mitochondrial damage causes inflammation via cGAS-STING signaling in ketamine-induced cystitis45
Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3/IL-1β/IL-6/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 rand44
HMGB1: key mediator in digestive system diseases44
IL-33, a neutrophil extracellular trap-related gene involved in the progression of diabetic kidney disease44
Viperin deficiency promotes dendritic cell activation and function via NF-kappaB activation during Mycobacterium tuberculosis infection41
The role of dietary fibre in lung inflammation: microbiota, metabolites, and immune crosstalk40
IL-1 receptor antagonist: etiological and drug delivery systems overview39
A suitable model to investigate acute neurological consequences of coronavirus infection39
Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues38
Navigating the complex landscape of DPP4 inhibition in inflammation: from novel mechanisms to unresolved translational challenges37
Mitochondrial proteomics reveals the impact of Estrogen in enhancing energy metabolism of patient-derived fibroblast-like synoviocytes in rheumatoid arthritis37
Annexin A1 is crucial during Toxoplasma gondii infection promoting the modulation of inflammation and intestinal and central nervous system barrier functions34
A pain from the nose to the head: neurological commitment during long COVID33
Successful treatment of refractory erythrodermic pemphigus foliaceus with low-dose rituximab and intravenous immunoglobulin33
0.27450680732727